Search
Axsome Therapeutics Inc
AXSMAdd to Watchlist
144.430USD
+0.980+0.68%
Close 10-30 16:00（ET）
7.57BMarket Cap
LossP/E TTM
Axsome Therapeutics Inc (AXSM) Stock Price Target & Forecast
Analyst Rating
Based on 23 analysts giving stock ratings to Axsome Therapeutics Inc in the past month.
Buy
9 Strong Buy
13 Buy
1 Hold
0 Sell
0 Strong Sell
Target Price
281.838USD+96.39%
AXSM Analyst Recommendation Trends
In the current month, AXSM has received 13 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. AXSM average Analyst price target in the last month is 281.838.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
9
9
8
8
8
8
8
7
13
13
13
13
12
12
12
12
1
1
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
23
23
22
22
21
21
21
20
AXSM Analyst Rating for Peer Comparison
Updated: Nov 1, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Biogen Inc
BIIB
10
17
10
1
0
38
Amgen Inc
AMGN
4
9
19
3
1
36
Eli Lilly and Co
LLY
10
19
3
1
0
33
Vertex Pharmaceuticals Inc
VRTX
10
17
5
0
1
33
Alnylam Pharmaceuticals Inc
ALNY
5
18
9
0
0
32
AbbVie Inc
ABBV
8
18
6
0
0
32
Neurocrine Biosciences Inc
NBIX
13
14
4
0
0
31
Merck & Co Inc
MRK
7
15
9
0
0
31
Bristol-Myers Squibb Co
BMY
5
6
18
1
0
30
Gilead Sciences Inc
GILD
7
18
5
0
0
30
Financial Forecasting
Based on analysts' estimates, AXSM EPS is projected to reach -0.587 in FY2026Q3, following reported EPS of -0.991 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.67
-0.90
-0.84
-0.59
0.01
Actual
-0.56
-1.26
-0.99
--
--
Surprise
+15.74%
-40.70%
-17.27%
--
--
FAQs
What is Axsome Therapeutics Inc's expected revenue for the next quarter?
Axsome Therapeutics Inc's expected revenue is 249.93M.
What is Axsome Therapeutics Inc's price target?
Analysts forecast that Axsome Therapeutics Inc's price target is USD 281.84, with the highest forecast at USD 380.00 and the lowest forecast at USD 246.00.
How have Axsome Therapeutics IncAXSM's recent earnings per share performed?
The market expectation was USD -0.99, while Axsome Therapeutics IncAXSM's earnings per share (EPS) for the previous quarter was USD -1.26. EPS for the next quarter is expected at USD -0.59.
What is the analyst rating for Axsome Therapeutics Inc?
Based on the ratings of Axsome Therapeutics Inc's stock from 23 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.